ERBB2 and breast cancer: Both the GeparSepto study and our data showed that TP53 mutations were more common in HER2-zero breast cancer than HER2-low breast cancer, but again the subtype analysis did not reveal any differences, which suggested that TP53 mutations were notably influenced by HR expression rather than HER2 expression [7, 32].